- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03894501
Pilot of Mindfulness Oriented Recovery Enhancement in MethadoneTreatment
Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for Opioid Use and Chronic Pain Management Pilot
Study Overview
Status
Conditions
Detailed Description
This pilot study is a 2-arm individually randomized controlled trial design in which outcomes of MMT patients randomized to MORE are compared to outcomes of those randomized to treatment as usual (TAU). In the pilot study (R21; N=30), we will randomize MMT patients with chronic pain to MORE (n=15) or TAU (n=15). This study phase will focus on establishing study feasibility in recruiting, retaining, and following up study participants before progressing to a larger Phase II clinical trial (R33, N=150). Participants with pain who are receiving MMT for an opioid use disorder (OUD) will be recruited from two methadone clinics in New Jersey.
Participants will be recruited through flyers posted in the clinics, being approached by research assistants in the waiting room of their usual methadone clinic, and referral by clinic staff. The number of individuals who contact the study staff through the flyers or referral and who are approached by study staff in the clinics will be tracked. Number of individuals who refuse study participation and who consent to the study will also be tracked. If an individual is interested in study participation, a trained research assistant will lead the individual through the informed consent process in a private space.
Since MORE is a closed group, we will randomize cohorts of 14-16 participants (depending on speed of recruitment) at each site to TAU or MORE with block randomization. Once we 14-16 participants at a particular clinic, we will randomize participants to MORE or TAU, and the MORE group will begin.
Participants randomized to the MORE condition will participate in eight, weekly, two-hour group sessions led by a clinic or study counselor. Each session will contain 6-8 participants and take place in a private room at the methadone clinic. Attendance at each session and reasons for missing sessions will be recorded Participants randomized to the control condition will continue receiving treatment as usual.
All study participants will partake in a total of three interviews lasting up to 90 minutes and occurring at baseline, 8- and 16- weeks post-baseline in private rooms in the methadone clinics. Each participant will also have a urine or saliva sample collected during each assessment. All attempts to reach participants to schedule follow-up assessments will be tracked. Participants will also complete cognitive testing (for approx. 30-45 minutes) at baseline and 8-weeks and ecological momentary assessments (EMA) conducted via smartphones, which will be provided to each participant by study staff. EMA participation will require the participant to respond to twice-daily prompts in which they will be asked a series of brief questions regarding their current mood and exposure to opioid triggers. Additionally, subjects will be asked to initiate responses when they experience serious craving or relapse to opioid use. Each EMA assessment will last approximately 3-5 minutes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Rutgers Robert Wood Johnson Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older
- English-speaking
- Been in methadone treatment for at least 3 months
- Experience a non-malignant pain (with an intensity level of 8 or higher on the Gracely Box Scale) for a duration of 2 months or longer.
Exclusion Criteria:
- Exhibit cognitive impairment (score <24 on the Mini Mental Status Exam)
- Exhibit psychosis (positive SCID Psychotic Screen),
- Are at suicidal risk (positive score on ASQ Suicide Risk Screening Tool)
- Unable to attend group sessions due to distance, work, commitments or other logistical problems,
- Are currently pregnant or breastfeeding
- Are planning to be pregnant or breastfeeding the next 16 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mindfulness Oriented Recovery Enhancement
The Mindfulness Oriented Recovery Enhancement arm will participate in eight, weekly, two-hour group sessions.MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion.
Each session begins with a mindful breathing meditation, followed by a debriefing session.
The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life.
During this debrief of the homework.
Next, new psychoeducational material is introduced.
Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation.
Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
|
MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion.
Each session begins with a mindful breathing meditation, followed by a debriefing session.
The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life.
During this debrief of the homework.
Next, new psychoeducational material is introduced.
Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation.
Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
Other Names:
|
Other: Methadone program behavioral treatment as usual
In the methadone programs, clients typically come to the clinic regularly to get their methadone dose.
Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment.
Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups.
Also, some clients may choose to go to voluntary counseling, educational, or support groups.
|
In the methadone programs, clients typically come to the clinic regularly to get their methadone dose.
Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment.
Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups.
Also, some clients may choose to go to voluntary counseling, educational, or support groups.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study Interest
Time Frame: Baseline
|
The number of individuals who express interest in the study.
|
Baseline
|
Study Refusal
Time Frame: Baseline
|
The number of individuals who who refuse participation when offered.
|
Baseline
|
Individuals Screened
Time Frame: Baseline (study enrollment)
|
The number of individuals screened and eligible/ineligible.
|
Baseline (study enrollment)
|
Individuals Consented.
Time Frame: Baseline (study enrollment)
|
The number of individuals consented.
|
Baseline (study enrollment)
|
Refusal After/During Consent Process.
Time Frame: Enrollment
|
The number of individuals who refuse participation after/during consent process.
|
Enrollment
|
Mean Sessions Completed
Time Frame: At 8-weeks (post treatment period completion).
|
The mean number of sessions completed by study participants in the MORE intervention.
|
At 8-weeks (post treatment period completion).
|
Percentage of Sessions Completed
Time Frame: At 8-weeks (post treatment period completion).
|
The mean percentage of sessions completed by study participants randomized to MORE.
|
At 8-weeks (post treatment period completion).
|
Number Who Drop Out
Time Frame: At 16 weeks.
|
Number of participants who drop out of the study.
|
At 16 weeks.
|
Percentage Who Drop Out
Time Frame: At 16 weeks.
|
Percentage of participants who drop out of the study.
|
At 16 weeks.
|
Baselines Completed
Time Frame: At baseline,
|
The number of participants who complete baseline assessments.
|
At baseline,
|
Percentage Baselines Completed
Time Frame: At baseline,
|
Percentage of people who completed baseline assessments.
|
At baseline,
|
8-weeks Completed
Time Frame: At 8-weeks.
|
The number of participants who complete 8-week assessments.
|
At 8-weeks.
|
Percentage 8-Weeks Completed
Time Frame: At 8-weeks.
|
Percentage of participants who completed 8-week assessments.
|
At 8-weeks.
|
16-Weeks Completed
Time Frame: At 16-weeks.
|
The number of participants who completed 16-week assessments.
|
At 16-weeks.
|
Percentage of 16-Weeks Completed
Time Frame: At 16-weeks.
|
Percentage of participants who completed 16-week assessments.
|
At 16-weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Days of Illicit Drug Use
Time Frame: 16-weeks
|
Research staff asked participants if they used various drugs (i.e., heroin, cocaine, opioids, marijuana, amphetamines, inhalants, hallucinogens, benzodiazepines, zolpidem, methylphenidate, or other drugs) in the past 30 days and the number of days of use for each drug in the past 30 days.
"Days of illicit drug use" was determined by counting the number of days each participant used drugs based on past-30 day self-reports at the16-week assessments.
|
16-weeks
|
Days of Illicit Opioid Use
Time Frame: 16-weeks
|
Research staff asked participants if they used illicit opioids in the past 30 days and the number of days of use for each drug in the past 30 days.
"Days of illicit opioid use" was determined by counting the number of days each participant used illicit opioids based on past-30 day self-reports at the 16-week assessment.
|
16-weeks
|
Opioid Craving
Time Frame: 16-weeks
|
Research staff assessed opioid craving with a version of the Penn Alcohol Craving Scale (PACS; Flannery et al., 1999) that was adapted to assess craving to opioids at 16-weeks.
Scores range from 0 to 36.
Higher scores indicate greater craving.
|
16-weeks
|
Pain Level.
Time Frame: 16-weeks
|
Pain was assess with the pain subscale (i.e., bodily pain severity and interference) of the RAND 36-Item Short Form Health Survey.
Scores range from 0 to 100, with higher scores indicating better functioning, health, and well-being and less pain, limitations, and symptom severity or interference as compared to lower scores.
|
16-weeks
|
Depression Level.
Time Frame: 16-weeks
|
Depression was measured with Center for Epidemiologic Studies Depression Scale (CES-D).
The CES-D scale is a widely used valid and reliable measure that consists of 20 items with potential scores ranging from 0 to 60.
A score above 16 on the CES-D indicates clinically significant symptoms of depression.
Higher scores on the CES-D indicates greater depression.
|
16-weeks
|
Anxiety Level.
Time Frame: 16-weeks
|
Anxiety was measured with the Beck Anxiety Inventory (BAI).
The BAI is also a widely used, reliable, and valid scale that consists of 21 items with potential scores ranging from 0 to 63.
A score of 16 or higher indicates clinically sig-nificant symptoms of anxiety.
A higher score on the BAI indicates greater anxiety.
|
16-weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nina A Cooperman, PsyD, Rutgers Robert Wood Johnson Medical School
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018001127
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
Clinical Trials on Mindfulness Oriented Recovery Enhancement
-
University of UtahCompletedSubstance Use | Mindfulness | Psychological Well-beingUnited States
-
National University of Natural MedicineRecruitingLumbar RadiculopathyUnited States
-
University of UtahRecruitingOpioid Use | Chronic Pain SyndromeUnited States
-
University of UtahPatient-Centered Outcomes Research InstituteActive, not recruiting
-
University of FribourgUniversity of Zurich; University of Utah; University of LausanneNot yet recruitingFibromyalgiaSwitzerland
-
University of Missouri-ColumbiaMedical University of South CarolinaRecruiting
-
University of MontanaNational Institute of General Medical Sciences (NIGMS)TerminatedOpioid-use DisorderUnited States
-
Massachusetts General HospitalTerminatedOpioid-use DisorderUnited States
-
University of UtahCompletedChronic Pain | Opioid Use DisordersUnited States
-
University of UtahUnited States Department of DefenseCompletedChronic PainUnited States